EFX的耐受性良好，最常见的不良事件是1级或2级胃肠道事件（腹泻、恶心和食欲增加）。 1例接受EFX治疗的患者因恶心而停药，1例在撤回同意后停药。

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Equifax Inc (NYSE:EFX) showcases robust revenue growth and operational efficiency in its latest quarterly report. Strategic positioning in credit information services and workforce solutions ...

Equifax Inc. Annual stock financials by MarketWatch. View the latest EFX financial statements, income statements and financial ratios.

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Equifax faces growth headwinds, premium valuation, and flat price action despite AI and cloud investments, with limited ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...